NCT02364596

Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of a single vaccination of an investigational vaccine against Staphylococcus aureus (SA4Ag) in healthy adults aged 18 to \<65 years.

Conditions

• Staphylococcal Infections

Interventions

Type	Name	Description
BIOLOGICAL	SA4Ag vaccine	Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
PROCEDURE	Blood sample	Blood for immunogenicity will be collected from all subjects at various timepoints.

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2015-02-18
• Last updated: 2015-04-03

Locations

2 sites across 1 country: United States